Very encouraging statement from medical authorities in Germany’s Tageschau article. They will consider EUA on interim data (Brazil critical patients in our case due possibly as early as August):

"Such so-called dampening immunomodulators, which slow down an excessive immune reaction, could increasingly come onto the market in the near future. Vfa spokesman Hömke refers to several remedies that are in phase III and that, when the positive ones are found Interim results confirm that approval could be submitted in the next few months. These include drugs MK-7110 from MSD, LERONLIMAB from CytoDyn and Siltuximab from Eusa Pharma. "